NCT05514990 2025-11-14
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
University of Southern California
Phase 1/2 Active not recruiting
University of Southern California
National Cancer Institute (NCI)
Emory University
University of Southern California
University of Leeds
National Cancer Institute (NCI)